LAG3 and melanoma: For example, in vitro studies have shown that inhibition of LAG-3 signaling in TILs from patients with melanoma restores the ability of CD4+ and CD8+ T cells to secrete IFN-γ, thereby enhancing their antitumor activity (25, 26).